IkT-001Pro regulatory update

Inhibikase said FDA granted Orphan Drug designation to imatinib to treat progressive multifocal leukoencephalopathy (PML). Imatinib, a BCR-ABL tyrosine kinase inhibitor, is the active ingredient in t...